This is a randomized clinical trial that was conducted in the operating room of the Rajaie cardiovascular, Medical and research center after obtaining permission from the ethics committee (rhc.ac.ir.rec.1396.41) from October 2016 to March 2017. Approved proposal was registered at the Iranian center for clinical trials (IRCT) (IRCT20171002036506N2).
Inclusion criteria was patients who were candidates for isolated elective coronary artery bypass graft surgery and consensus form was obtained. Exclusion criteria included emergent, re-do or concomitant valve surgeries, history of cardiac arrhythmia, left ventricle ejection fraction of less than 30%, severe aortic insufficiency, end stage renal disease, history of hypersensitivity to lidocaine. Also patients who needed re-exploration for post-operative bleeding control were excluded from this study. Demographic data and underlying diseases, clinical information and arterial blood gas, post-ischemic time events (Arrhythmia, need for DC shock, electrolyte imbalance), and early post-operative data including the occurrence of arrhythmia, need for inotrope and anti-arrhythmic drugs, ECG and echocardiographic findings. Based on the previous study (
11), considering 90% strength of the study and the significance level of 0.05, the number of patients required for study in each group was estimated to be 50.
Statistical analysis was performed on raw data using SPSS 22 software (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.). One-sample Kolmogorov Smirnov test and Student’s t test (Mann Whitney U), Chi-square test and Fisher’s exact test were used. Multivariate analysis was performed using logistic regression models. P value less than 0.05 was considered statistically significant.
Balanced block randomization was used to assign patients to the two study groups of 1, the group of cardioplegic solution containing procaine hydrochloride (Shahid Ghazi Pharmaceutical Co. Tabriz, Iran) and 2, the group of cardioplegic solution with lidocaine additive. The cardioplegic solution was prepared according to the conditions and requirements under the supervision of the center’s pharmacist and the pharmaceutical department, and then the drugs were numbered and blinded by sealed envelopes method. Therefore none of the perfusionist, nurses, surgeons and researcher knew about the type of cardioplegic solution used. To evaluate the effect of these two drugs, the cardioplegic solution was prepared in such a way that, apart from the two antiarrhythmic drugs, there was no difference in electrolytes, osmolarity and their formulation. The composition and formulation of the cardioplegic solution are similar to the solution of ST.Thomas1, which is made and consumed in European countries by Martindale pharmaceuticals company with the registration number pl01883 / 0012. The latest drug review date was in February 2015, and is also being used in Australia under the name of DBL sterile cardioplegia concentrate (https://www.medicines.org.UK) (
13). The Iranian sample is a cardioplegic solution prepared by Shahid Ghazi company, which in terms of composition and content is similar to the solution produced in Australia. This solution is in a volume of 50 mL; diluted in 1 liter of the ringer serum at 4°C. Each liter of diluted solution contains 44 milliequivalent (mEq) of potassium, 64 mEq of magnesium, 147 mEq of sodium and 4.5 mEq of calcium, and one millimole of procaine hydrochloride with osmolarity of 300 to 320 and a pH of about 7.4 to 7.6. This solution was used as the cardioplegic solution containing procaine hydrochloride and the other solution was prepared with the same formulation, osmolarity and PH, and only lidocaine 2% has been replaced instead of Procaine hydrochloride containing 5 cc (equivalent to 100 mg). Blood cardioplegia was used and electrolytes, especially potassium, were within the normal range and were given 1 to 1 cardioplegia and blood. Cardioplegic solutions were administered via aortic root at a rate of 300 cc per minute, for three minutes until a complete cardiac arrest was achieved. The method of induction and maintenance of anesthesia, surgical procedures, perfusion and the pump device, the model of the oxygenator, the method of priming, heparinization, the infusion method of cardioplegic solution (antegrade in the root of the aorta) and restoration of the effect of heparin by protamine were considered to be administered similarly for all patients. All CABGs were performed by the same surgical team. Demographic data including age, sex, weight, height, BSA and also troponin levels and preoperative ejection fraction, history of hypertension, thyroid, smoking, history of MI and angioplasty and beta blocker drugs were recorded. After aortic de-clamp, if the rhythm returned in 3 - 5 minutes spontaneously, it would be recorded as a self-reversal rhythm, otherwise lidocaine and magnesium are injected (potassium values are checked to make sure they are in the normal range). Variables such as hemodynamic parameters and arterial blood gas parameters were measured at the entry to the operating room, during the cross-clamp time, after aortic de-clamp, at the end of bypass pump, at the entrance to the ICU and after the extraction of the tracheal tube in the ICU. The volume and frequency of cardioplegic solution administration, the rate of spontaneous return to baseline heart rhythm, the need for electrical cardioversion after aortic de-clamp, the frequency of arrhythmia after declamping, the duration of arrhythmia, the need for lidocaine, magnesium and potassium were all recorded by perfusionist in the registered questionnaires. Also early postoperative data including the need for inotrope or pacemaker, or atrial and ventricular dysrhythmia, new ST-T changes in ECG, serum troponin level, mechanical ventilation time, ICU stay and post-operative echocardiographic findings have been collected.